Tirzepatide for Type 2 Diabetes (SURPASS-SWITCH Trial)
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Waitlist Available
Sponsor: Eli Lilly and Company
No Placebo Group
Prior Safety Data
Approved in 6 jurisdictions
Trial Summary
What is the purpose of this trial?The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
Eligibility Criteria
Adults with type 2 diabetes currently on a stable dose of dulaglutide can join this trial. They should have an HbA1c level between ≥7.0% and ≤9.5%, a BMI of ≥25 kg/m², and may be taking up to three other oral diabetes medications. Exclusions include severe heart failure, very low kidney function, history of pancreatitis or certain thyroid cancers, type 1 diabetes, serious eye problems due to diabetes, recent cardiovascular events or weight loss treatments.Inclusion Criteria
I have type 2 diabetes.
Exclusion Criteria
I have a history of pancreatitis.
I have used weight loss medications in the last 90 days.
I have a history of medullary thyroid cancer or MEN2 in my family or myself.
I have a serious diabetic eye condition needing immediate treatment.
My kidney function is significantly reduced.
I had to lower my dulaglutide dose because it was too harsh, and couldn't increase it again.
I have severe heart failure that limits my daily activities.
Treatment Details
The study is testing the effectiveness and safety of switching from weekly doses of dulaglutide to tirzepatide in comparison to increasing the dose of dulaglutide for adults with type 2 diabetes. Participants will either switch medication or receive higher doses.
2Treatment groups
Experimental Treatment
Active Control
Group I: TirzepatideExperimental Treatment1 Intervention
Participants will receive tirzepatide subcutaneously (SC)
Group II: DulaglutideActive Control1 Intervention
Participants will escalate their dulaglutide dose SC.
Tirzepatide is already approved in United States, European Union, Canada, Australia, United States, United Kingdom for the following indications:
🇺🇸 Approved in United States as Mounjaro for:
- Type 2 diabetes
🇪🇺 Approved in European Union as Mounjaro for:
- Type 2 diabetes
🇨🇦 Approved in Canada as Mounjaro for:
- Type 2 diabetes
🇦🇺 Approved in Australia as Mounjaro for:
- Type 2 diabetes
🇺🇸 Approved in United States as Zepbound for:
- Weight loss
- Moderate to severe obstructive sleep apnea
🇬🇧 Approved in United Kingdom as Zepbound for:
- Weight loss
Find a clinic near you
Research locations nearbySelect from list below to view details:
Alliance for Multispecialty Research, LLCNorman, OK
Intend Research, LLCNorman, OK
Southern Endocrinology AssociatesMesquite, TX
Clinvest Research LLCSpringfield, MO
More Trial Locations
Loading ...
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor